6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol

• ChemBase ID: 1145
• Molecular Formular: C12H20N2O3
• Molecular Mass: 240.2988
• Monoisotopic Mass: 240.14739251
• SMILES: OC(CNC(C)(C)C)c1nc(c(O)cc1)CO
• Canonical SMILES: OCc1nc(ccc1O)C(CNC(C)(C)C)O
• InChI: InChI=1S/C12H20N2O3/c1-12(2,3)13-6-11(17)8-4-5-10(16)9(7-15)14-8/h4-5,11,13,15-17H,6-7H2,1-3H3
• InChIKey: VQDBNKDJNJQRDG-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol
• IUPAC Traditional name: pyrbuterol; pirbuterol
• Brand Name: Maxair
• Synonyms: Pirbuterol hydrochloride; Pirbuterolum [inn-latin]; Pirbuterol; α6-[[(1,1-Dimethylethyl)amino]methyl]-3-hydroxy-2,6-pyridinedimethanol Hydrochloride; Broncocor; CP 24314-1; Exirel; NSC 355078; Pyrbuterol Hydrochloride; Pirbuterol Dihydrochloride

Database IDs

• CAS Number: 38677-81-5; 38029-10-6
• PubChem SID: 46506379; 160964608
• PubChem CID: 4845

CALCULATED PROPERTIES

JChem

• Acid pKa: 8.786121
• H Acceptors: 5
• H Donor: 4
• LogD (pH = 5.5): -3.1210253
• LogD (pH = 7.4): -1.7822901
• Log P: -0.6583083
• Molar Refractivity: 64.7447 cm^3
• Polarizability: 25.692781 Å^3
• Polar Surface Area: 85.61 Å^2
• Rotatable Bonds: 5
• Lipinski's Rule of Five: true

ALOGPS 2.1

• Log P: 0.38
• LOG S: -1.59
• Solubility (Water): 6.22e+00 g/l

DETAILS

DrugBank - DB01291

• Drug Groups: approved
• Description: Pirbuterol is a beta-2 adrenergic bronchodilator. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing in a concentration between 10-50%. The precise function of these receptors has not been established.; ; The pharmacologic effects of beta adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (AlP) to cyclic-3? ,5?-adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
• Indication: For the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible bronchospasm including asthma.
• Pharmacology: Pirbuterol is a beta-2 adrenergic bronchodilator. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 adrenergic receptors compared with isoproterenol. While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing in a concentration between 10-50%. The precise function of these receptors has not been established.
• Toxicity: As with all sympathomimetic aerosol medication, cardiac arrest and even death may be associated with abuse of pirbuterol.
• Affected Organisms: Humans and other mammals
• Half Life: The plasma half-life measured after oral administration is about two hours.
• External Links: RxList; Drugs.com

Toronto Research Chemicals - P502500

An analogue of Albuterol (A514500) with β2-adrenergic stimulating activity. Bronchodilator.

REFERENCES

• Constantine, J.W., et al.: J. Pharmacol. Exp. Ther., 208, 371 (1979)
• Awan, N.A., et al.: Clin. Res., 28, 17 (1979)
• Richards, D.M., et al.: Drugs, 30, 6 (1979)